Sangamo Therapeutics, Inc.

NasdaqGS:SGMO 주식 보고서

시가총액: US$180.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sangamo Therapeutics 배당금

배당금 기준 확인 0/6

Sangamo Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률1.9%
다음 배당금 지급일n/a
전 배당일n/a
주당 배당금n/a
주당 순이익-US$1.20
배당 수익률 예측0%

최근 배당금 업데이트

업데이트 없음

Recent updates

There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Aug 03
There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking

Jul 23

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

Jun 19
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

May 29
We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

May 14
This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Mar 23
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

Mar 16
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Mar 09
We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Feb 02
Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Dec 04
Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Sep 11
Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Aug 15
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Aug 08
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

May 30
Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

May 13
Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

Apr 11
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Dec 20
We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy

Sep 22

Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sep 18
Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead

Aug 31

Sangamo Therapeutics: Cheap, But Justifiably So

Aug 09

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

May 08
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?

Apr 11
Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?

Sangamo Therapeutics: Lost In Transition From Lab To Clinic

Feb 24

Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?

Jan 10
Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?

Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December

Dec 03

We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow

Sep 22
We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow

Sangamo Therapeutics: Finding An Opportunity To Reload

Aug 21

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 SGMO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: SGMO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.


시장 대비 배당 수익률

Sangamo Therapeutics 시장 대비 배당 수익률
SGMO 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트배당 수익률
회사 (SGMO)n/a
시장 하위 25% (US)1.4%
시장 상위 25% (US)4.3%
업계 평균 (Biotechs)1.9%
애널리스트 예측 (SGMO) (최대 3년)0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SGMO 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SGMO 의 배당 수익률을 평가할 수 없습니다.


주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SGMO 의 지급 비율을 계산하기에는 데이터가 부족합니다.


주주에 대한 현금 배당금

현금 흐름 범위: SGMO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.


강력한 배당금 지급 기업 알아보기